Business Wire

Earnix Highlights the Potential of Synthetic Data in Specialty Insurance

Share

Earnix, the leading global provider of AI-based SaaS solutions for financial services, today releases a high-level report highlighting the transformative potential of synthetic data to accelerate profitable growth and risk understanding in the context of the unique specialty London insurance market.

The white paper Reshaping London’s Specialty Market -The Impact of Technology and Datahighlights the pivotal role that synthetic data - data that is produced, rather than gathered - will play in the future success of the market.

While synthetic data has been utilized in academia for decades, it's only recently gained traction in mainstream commercial applications. According to Gartner, synthetic data accounted for just 1% of data in 2021 but is projected to grow to 60% by 2024. Technological advancements like generational adversarial networks, transformers, and large language models have significantly increased the speed and volume of synthetic data created.

At the same time, the increasing demand for data in specialty insurance has prompted underwriters and brokers to begin harnessing synthetic data to supplement existing datasets, improving risk assessment efficiency. This is because synthetic data offers solutions to several key challenges in the London Market:

  1. Filling Data Gaps: Specialty insurers can harness synthetic data to access necessary data for product development and testing without compromising security or customer privacy. This has led to a surge in innovative ideas and technology deployment in insurance.
  2. Privacy and Security: Synthetic data maintains confidentiality while enabling critical analysis. In a world of widespread data availability, synthetic data techniques are essential to ensure customer data is not vulnerable to identity theft or fraud.
  3. Analytical Support: Synthetic data supports more accurate modeling, simulation, and testing, particularly in assessing extreme or rare events crucial for the specialty market, such as floods or hurricanes and fraud detection. Insurers can simulate these events to develop robust risk models without waiting for actual occurrences.
  4. Simulations, Stress Testing, and Data Expansion: Generating synthetic data improves the performance of predictive models, enhancing fraud detection and other analytical insights. It allows insurers to simulate and stress-test models in new situations, enabling them to introduce new products or expand into new segments or territories with limited existing data.

Earnix CEO Robin Gilthorpe said:

“The digital transformation of the London market’s complex specialty lines of business has only just begun. While it is a market-wide and fundamental shift in the way specialty insurers and reinsurers do business, it is not a one-size-fits-all solution. However, synthetic data coupled with AI, machine learning, and advanced analytics, holds promise for addressing various challenges in specialty insurance, including data gaps, privacy and security concerns, and fraud detection, among others.

Data plays a crucial role in revenue, profitability, and market share- particularly in this complex market where insight at a granular level can make a significant difference at a macro level. Specialty brokers and insurers know that in this rapidly evolving market, the ability to grow through change is paramount. Our white paper underscores the pivotal role of synthetic data in reshaping the London Market and outlines the next steps available to specialty insurers to harness the unparalleled opportunities for informed decision-making and enhanced operational efficiency.”

Download the report here.

For more information about Earnix, please visit www.earnix.com.

About Earnix

Earnix is the premier provider of mission-critical, cloud-based intelligent solutions across pricing, underwriting, rating, and product personalization. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. Earnix has been innovating for insurers and banks since 2001, with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. For more information please visit: earnix.com.

Contact Earnix via LinkedIn, X, and Facebook. Read the Earnix blog.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Krystina Puleo
Global Director of External Communications
press@earnix.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease31.8.2024 17:00:00 CEST | Press release

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) study programme, at the European Society of Cardiology (ESC) Congress 2024. Gender inequalities in CV disease treatment and LDL-C goal attainment Raised low-density lipoprotein cholesterol (LDL-C) is a key modifiable contributor to risk of cardiovascular major events. It has been shown that for every 1 mmol/L reduction in LDL-C, there is a 22% reduction in major cardiovascular events after 1 year.7,8 Female patients in Europe who are at high or very high CV risk were undertreated and less achieved guideline-recomm

Suzano completes purchase of 15% stake in Lenzing AG31.8.2024 00:40:00 CEST | Press release

Suzano, the world's largest pulp producer, today announces the completion of its acquisition of a 15% stake in Lenzing AG, the Vienna-listed leading global supplier of sustainable premium cellulosic fibres for the textile and non-wovens industry, from B&C Group. As announced in June this year, the transaction value is EUR 230 million (or EUR 39.70 per share). The agreement was subject to regulatory approval, which was granted without restrictions. The long-term partnership between Suzano and B&C Group establishes that Suzano has the right to hold two seats on Lenzing’s Board and the option to acquire an additional 15% stake from B&C Group until the end of 2028. Following the sale of the 15% stake, B&C Group now holds 37.25% of Lenzing’s share capital. Lenzing is a leading global supplier of premium wood-based cellulosic fibers (lyocell, modal, and viscose) for the production of clothing, home textiles, hygiene products, and non-woven materials. Beto Abreu, CEO of Suzano, said: “Lenzing

Ant International Collaborates with Brazilian Partners to Drive Financial Inclusion with Innovative Credit Tech Solutions30.8.2024 20:46:00 CEST | Press release

Ant International, a digital payment and financial technology leader, today announced its strategic initiative to provide AI-driven credit technology solutions designed to empower local partners and advance financial inclusions in Brazil. As a major milestone, Ant International has formed a strategic partnership with Dock, a leader in payments and banking technology in Latin America. This collaboration aims to enhance the credit management capability and infrastructure efficiency for Dock’s clients, which include financial institutions, retailers, fintech start-ups, etc. The shared vision is to make credit services more inclusive for market segments that are currently insufficiently served, such as micro, small and medium-sized enterprises (MSMEs). In the initial phase of the collaboration, Ant International’s AI-driven credit tech solutions, including an automated and intelligent risk management engine, will be explored for integration into Dock One platform. This initiative aims to s

Wipro Appoints Srikumar Rao as Global Head of Its Engineering Edge Business Line30.8.2024 16:20:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Srikumar Rao as Global Head of its Engineering Edge Business Line, effective from October 5, 2024. Srikumar succeeds Harmeet Chauhan, who is stepping down to pursue opportunities outside the organization. Srikumar will report to Srini Pallia. Srikumar has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Chief Operating Officer (COO) of Wipro Engineering Edge (WEE) and Global Practice Head of Embedded Systems. His work has spanned several markets, selling and delivering specialized Engineering, Research, and Development (ER&D) services to Software & Internet, Semiconductor, Automotive, Manufacturing, and Communications clients. In his new role, Srikumar will continue to scale and strengthen Wipro’s engineering prowess. He will also be responsible for defining the vision

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress30.8.2024 12:00:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously published in TheNew England Journal of Medicine. As previously reported, the HELIOS-B study met all 10 of its primary and secondary endpoints, across both the overall and monotherapy populations, with statistical significance. Enrolled patients were predominantly New York Heart Association (NYHA) Class I or II with wild-type disease and had been diagnosed by non-invasive methods, with substantial concurrent treatment with available standard of care treatments such as tafamidis and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye